Latest biopharmaceuticals Stories

LAUSANNE, Switzerland and SUZHOU, China, April 18, 2013 /PRNewswire/ -- Suzhou Ascepion Pharmaceuticals, Inc. (Ascepion), a Chinese leading biotech company focusing on the discovery and development of world-class molecular targeted innovative drugs and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies, announced today that Debiopharm will support further development in China of Debio 1144, a small molecule in preclinical development...

BALTIMORE, Feb. 25, 2013 /PRNewswire/ -- Gliknik Inc., a privately held biopharmaceuticals company, today announced the appointment of Incyte Corporation President and Chief Executive Officer Paul A. Friedman, M.D., to its Board of Directors. Dr. Friedman, a seasoned pharmaceutical industry executive with strong experience in management of R&D and corporate functions, joins Gliknik's board as the company is continuing to advance its pipeline of drug candidates targeting various...

NEWARK, Del. and BRYAN, Texas, Feb. 19, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO), and Caliber Biotherapeutics LLC (Caliber) today announced execution of a License and Collaboration Agreement for development and production of recombinant plant-based biopharmaceuticals using iBio's proprietary iBioLaunch(TM) technology and Caliber's unique and proprietary plant-based manufacturing capabilities. (Logo: http://photos.prnewswire.com/prnh/20120419/NY91086LOGO) (Logo:...

NEW YORK, January 30, 2013 /PRNewswire/ -- Today, Traders Insight announced new research reports highlighting Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ), Furiex Pharmaceuticals, Inc. (Nasdaq: FURX), Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), Prestige Brands Holdings, Inc. (NYSE: PBH) and Synta Pharmaceuticals, Inc. (Nasdaq: SNTA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links...

LONDON, January 30, 2013 /PRNewswire/ -- EmergingGrowth.com, a leading digital financial media company, discusses Sunesis Pharmaceuticals, Amgen, Inc., Gilead Sciences and Biogen Idec, Inc. The pharmaceutical sector is a very lucrative and competitive industry. And for emerging growth companies, it is difficult to make a meaningful impact in this cutthroat industry. Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) has built a highly experienced cancer drug...

LAUSANNE, Switzerland, January 9, 2013 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm) and Spinomix SA, a Swiss company advancing molecular diagnostic technologies, announced the closing of a Series A equity investment of $ 3 Million. The financing round was led by Debiopharm Group(TM). Significant participation and support is being provided by existing investors and a private US investor group with proven entrepreneurial experience. Debiopharm is a successful drug...

LAUSANNE, Switzerland and TOKYO, January 8, 2013 /PRNewswire/ -- Chugai Pharmaceutical Co., Ltd. ("Chugai") and Debiopharm GroupTM ("Debiopharm") announced today that on December 17, 2012, they entered into a licensing agreement regarding FF284 (called Debio 1347 by Debiopharm) discovered by Chugai and which is about to start clinical development in oncology. Under this license agreement, Chugai will grant Debiopharm an exclusive license to develop and commercialise...

BLUE BELL, Pa., Jan. 4, 2013 /PRNewswire/ -- Relmada Therapeutics, a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that Sergio Traversa, the company's Chief Executive Officer, will be presenting at the Biotech Showcase in San Francisco on Tuesday, January 8, 2013 at 1:45 PM Pacific Time. The presentation will include an overview of Relmada business and an update on the ongoing development programs of LevoCap, d-methadone,...

LAUSANNE, Switzerland, December 7, 2012 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, announces that Dr. Reddy's Laboratories Ltd. launched Pamorelin(R) LA in India for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer on December 3. Under the terms of the...

BALTIMORE, Oct. 8, 2012 /PRNewswire/ -- Gliknik Inc., a privately held biopharmaceuticals company creating new therapies for cancer and immune / inflammatory disorders, today announced that it has raised $4.9 million in Series B Financing. Baxter Ventures, an initiative created in 2011 by Baxter International Inc., led the Series B raise and is joined by existing investors. With the funding, Gliknik will further advance towards the clinic its IVIG-mimetic lead compound, GL-2045,...